Manufacturing News of Note—AveXis goes deeper on Zolgensma manufacturing; 76B opioid pills manufactured

Here is some news of note for the week:

Catalent Biologics and Novartis’ company AveXis have struck a long-term deal in which the biotech will have dedicated manufacturing space at a Catalent facility for the production of AveXis' Zolgensma, its newly approved gene therapy for spinal muscular atrophy. Release

Data recently released as part of a civil action show that U.S. drugmakers manufactured 76 billion oxycodone and hydrocodone pills from 2006 through 2012 as the opioid epidemic spread. Story

According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. Release